Skip to main content

Author: Frank Schuler

Is Hemp Protein An Overlooked Sector Of The Industry?

Protein consumption is one of the most important parts of the human diet. It is a nutrient that all humans need to grow and repair cells, particularly cells in muscles and bones. Daily protein consumption is necessary for humans to perform life functions properly.

When some people think of protein, they probably get visions of bodybuilders and powder mixes, or huge slabs of meat. However, as previously stated, all humans need protein in their diets, not just athletes who are trying to increase their muscle mass, and protein can be found in many different foods.

Protein is comprised of various amino acids, with amino acids often being referred to as ‘the building blocks of life.’ There are roughly 20 different amino acids, 11 of which human bodies create naturally. Those are referred to as ‘non-essential amino acids.’ Nine other amino acids cannot be made by the human body, and are referred to as ‘essential amino acids.’

Meat, while not the only source of protein on earth, is the most popular choice in many parts of the world. Plant-based proteins are becoming more popular for various reasons, which is a good thing from a sustainability standpoint.

Large-scale livestock operations, which is where much of the world’s meat comes from, collectively produce a significant carbon footprint. Whereas farming operations that produce plant-based proteins have a lower carbon footprint.

In recent years, as more humans have transitioned away from meat protein sources to plant-based ones, researchers have tried to figure out which plants are the best for producing protein, both from an output standpoint and a sustainability standpoint.

Soy is a popular plant-based protein, as are peas. Beans, nuts, and whole grains are other non-meat-based proteins that are commonly incorporated into human diets and protein products. But one plant, the hemp plant, may prove to be the best protein source of them all one day.

Hemp seed as a protein source for humans is not a new phenomenon, with evidence of its use for nourishment purposes going back at least 3,000 years. Although, the push to ‘optimize’ hemp seed and research how to get the most out of it is still a relatively new thing.

Popular plant-based proteins were never prohibited like hemp was, and in some areas, hemp is still prohibited. Prohibition has greatly hindered hemp research compared to other crops, including from a cultivar standpoint, as well as protein solubility.

Last year researchers associated with Cornell University in the United States analyzed multiple hemp cultivars to see which one possessed the best traits for various measurables.

“Hemp seed protein isolates (HPI) were extracted from seven commercial hemp cultivars, a Cornell breeding line, and a commercial hemp heart product, and their composition and functional properties were investigated. HPI contained different ratios of edestin, vicilin, and albumin proteins, which affected protein solubility and functionality.” the researchers stated.

“Higher protein solubility was associated with cultivars that contained more vicilin and albumin, which influenced the subsequent functional properties of HPI. Significant differences in water holding capacity (0.83-1.05 g water/g protein isolate), oil holding capacity (1.28-1.81 g oil/g protein isolate), foam capacity (52.9%-84.9%), and foam stability (68.1%-89.4%) were observed across HPI.” the researchers also stated.

“The relationship identified between hemp seed protein composition and functionality, in conjunction with the demonstration of an on-going hemp breeding line, suggest that continued, targeted development of hemp cultivars can improve its seed protein functional properties for ingredient utilization in plant-based foods.” the researchers concluded.

Hemp seed protein is very versatile from a product development standpoint, as many things can be created with hemp protein as a key ingredient, including butter, milk, powders, and breads. With demand for organic, plant-based proteins increasing, and hemp seed research also increasing, the future is bright.

It’s quite likely that hemp seed protein will supplant other popular protein sources someday, especially when considering the sustainability concerns associated with various crops and livestock operations that do not apply to the hemp plant.

Legalization Is Not Associated With Spikes In Cannabis-Related Psychosis

One of the most common mainstream media hit jobs in modern times involves opponents implying that cannabis reform alone has led to a spike in incidents of cannabis-related psychosis among consumers and patients.

Cannabis legalization, by every reasonable measure, has been an overwhelming success in jurisdictions that have allowed it, including in Canada where cannabis was first legalized for adult use in late 2018.

Researchers in Canada examined data involving incidents of cannabis-related psychosis and determined that legalization is not associated with spikes in such incidents. Below is more information about it via a news release from NORML:

London, Canada: The legalization of the Canadian marijuana market is not associated with increases in rates of cannabis-related psychosis, according to data published in the International Journal of Drug Policy.

A team of Canadian researchers examined regional changes in health services use and incidences of psychotic disorders during the months immediately following legalization. (Canada legalized marijuana possession and retail sales in October 2018.)

They reported, “We did not find evidence of increases in health service use or incident cases of psychotic disorders over the short-term (17 month) period following cannabis legalization.” They cautioned, however, that “a longer post-legalization observation period … is needed to fully understand the population-level impacts of non-medical cannabis legalization.”

The finding is consistent with the conclusions of a 2022 study published in the Canadian Journal of Psychiatry. Its authors similarly determined that the “implementation of Canada’s cannabis legalization framework was not associated with evidence of significant changes in cannabis-induced psychosis or schizophrenia ED [emergency department] presentations.”

In the United States, state-level marijuana legalization laws have not been associated with a statistically significant increase in psychosis-related health outcomes. Specifically, a 2022 paper published in the Journal of the American Medical Association (JAMA) Network Open found no association between the adoption of marijuana legalization and overall rates of psychosis-related diagnoses or prescribed antipsychotics.

Although the use of cannabis and other controlled substances tends to be more common among those with psychotic illnesses, studies indicate that lifetime incidences of marijuana-induced psychosis are relatively rare among those who do not have a prior psychiatric diagnosis. According to one recently published study, fewer than one-half of one percent of cannabis consumers had ever reported experiencing psychotic symptoms requiring medical intervention – a percentage that is lower than the rate associated with alcohol.
Full text of the study, “Impact of non-medical cannabis legalization with market restrictions on health service use and incident cases of psychotic disorder in Ontario, Canada,” appears in the International Journal of Drug Policy. Additional information is available from NORML’s op-ed‘Concerns surrounding cannabis and mental health must be placed in context, not sensationalized.

Medical Cannabis Use Associated With ‘Few Serious Adverse Events’

Canada first legalized cannabis for medical use in 1999, and then for adult use in 2018. Since that time, numerous suffering patients have benefitted from Canada’s modernized cannabis policies and the increased safe access that reform has created.

Meanwhile, many other nations still prohibit cannabis for medical use to some degree, although several of those nations are considering reforming their policies to permit such use. Opponents in those countries try hard to portray medical cannabis as being harmful, however, what does the science say?

Researchers in Canada recently conducted an analysis in which they examined medical cannabis use’s impact on the patients who consume it. Below is more information about it via a news release from NORML:

Montreal, Canada: Few patients authorized to consume medical cannabis products report experiencing serious side effects, according to data published in the journal Drug Safety.

McGill University researchers analyzed data from a cohort of nearly 3,000 authorized Canadian medical cannabis patients. Data regarding adverse events was collected by enrollees’ attending physicians over a period of several years.

A total of 108 patients (about four percent of the cohort) reported experiencing marijuana-related adverse events. The most frequently reported side effects were dizziness, somnolence, headache, nausea, and vomiting.

Patients with mental health disorders were no more likely than others to report side effects from cannabis treatment. The latter finding is consistent with data from a 2022 study, which found that authorized Canadian patients were at low risk for psychiatric hospitalizations resulting from their medical cannabis use.

The study’s authors concluded: “This is the first comprehensive, population-level prospective study to contribute evidence that MC [medical cannabis] is safe for a wide variety of symptoms. … No new safety concerns were identified relative to the published literature, although notable differences in AE [adverse events] profile between modes of administration and cannabinoid content ratios should be considered by health professionals.”

Full text of the study, “A descriptive analysis of adverse event reports from the Quebec Cannabis Registry,” appears in Drug Safety.

Can Cannabis Industry Waste Be Used To Make Supercapacitors?

The cannabis plant can be used for a myriad of purposes to benefit humans, and not just in a medical cannabis capacity. Researchers in Argentina recently examined using discarded cannabis material from the legal cannabis industry to see if it can be an effective component for supercapacitors.

Supercapacitors are organized based on their electrode configurations, being classified as either symmetric, asymmetric, or battery-type supercapacitors. A symmetric supercapacitor, which was the type at the heart of the recent study in Argentina, utilizes two similar electrodes.

Researchers conducting the study in Argentina were affiliated with CIFICEN, UNCPBA-CICPBA-CONICET, Universidad Nacional del Centro de la Provincia de Buenos Aires, and Instituto de Ingeniería Química. Results were published in the Journal of Energy Storage.

“This study proposes valorizing cannabis waste (stems and leaves) by producing and evaluating activated biocarbons as electrode materials for supercapacitors.” the team of investigators stated about their research.

“Cannabis waste were pyrolyzed at 500 °C; then activation conditions were varied from 60 to 180 min; the impregnation ratio was from 1.5 to 4.5 g KOH/g pyrolyzed waste and fixed temperature at 850 °C. Textural properties were evaluated through scanning electron microscopy, infrared spectroscopy, and N2 adsorption/desorption isotherms.” the team of researchers stated about their methodology.

“The electrochemical characterization was done using an alkaline electrolyte in a three and two-electrode configuration. Cyclic voltammetry, galvanostatic charge and discharge measurements, and electrochemical impedance spectroscopy were performed. Activated biocarbon reached high surface areas over 2500 m2g−1 and adequate porosity development.” researchers also stated.

Cannabis is primarily cultivated for human consumption, either for recreational use or medical use. However, not all parts of the cannabis plant are desirable for those purposes. Stems and leaves often get discarded. If that material can be successfully used to help make supercapacitors, supply would, in theory, be potentially plentiful.

“The best electrochemical performance was obtained at 0.1 Ag−1 achieving 195.83 Fg−1 as specific capacitance, 23.3 KWKg−1, and 54.40 WhKg−1 as power and energy density in the electrode cells. A symmetric solid-state supercapacitor of 2.78 F maximum capacitance at 7.5 mA and 1.2 V potential was developed. These results position activated biocarbon derived from cannabis residues as potential electrode materials in supercapacitors.” the researchers concluded.

This study’s research builds on previous research. According to previous research, batteries made from hemp last up to eight times longer compared to lithium-ion batteries. Scientists are using hemp bast fiber, which is often thrown away historically, to make batteries that can be used for almost anything that currently relies on lithium-ion batteries.

Cannabis Associated With Quality Of Life Improvements, Reduced Opioid Use

The cannabis plant has been used by humans for many centuries due to its wellness benefits. An example of that is cannabis’ inclusion in Emperor Shen Nung’s (regarded as the father of Chinese medicine) pharmacopeia.

It wasn’t until the 1900s and the rise of global cannabis prohibition that opponents started touting cannabis as being ‘bad for human health.’ Once prohibition was implemented across the globe, cannabis research was largely hindered resulting in many people unfortunately believing anti-cannabis propaganda.

Fortunately for compassion and logical reasoning, cannabis research has picked up exponentially in recent decades. A new study found that cannabis use is associated with improvements in quality of life, as well as a reduction in opioid use. Below is more information about it via a news release from NORML:

London, United Kingdom: Patients suffering from chronic pain, depression, anxiety, and other conditions report sustained improvements in their symptoms following the use of cannabis, according to observational data published in the journal Neuropsychopharmacology Reports.

British investigators assessed the safety and efficacy of plant-derived cannabis products (either oils, flower, or a combination of both) in a cohort of 1,378 patients enrolled in the UK Medical Cannabis Registry. Participants possessed a doctor’s authorization to access cannabis products. (Since 2018, healthcare specialists have been permitted to prescribe cannabis-based medicinal products to patients unresponsive to conventional medications.) Authors assessed the efficacy of cannabis at one, three, six, and twelve months.

Consistent with prior studies, patients reported reduced levels of anxiety, better sleep, and improvements in their health-related quality of life following cannabis treatment. Many patients also reported decreases in their daily opioid consumption – a finding that is also consistent with numerous other studies.

The study’s authors concluded: “There was an associated improvement in self-reported anxiety, sleep quality, and HRQoL [health-related quality of life] in patients treated with the CBMPs [cannabis-based medicinal products]. Those prescribed treatment formulations including dried flower were most likely to show a clinical improvement. … There was a reduction in opioid prescriptions at 1 month, 3 months, 6 months, and 12 months compared to the baseline… Most reported adverse events were mild to moderate, consistent with prior assessments of safety.”

Other studies assessing the use of cannabis products in patients enrolled in the UK Cannabis Registry have reported them to be effective for those suffering from chronic painpost-traumatic stressdepressiongeneralized anxietymigraineinflammatory bowel disease, and other afflictions.

Full text of the study, “An observational study of clinical outcome measures in patients treated with cannabis-based medicinal products on the UK Medical Cannabis Registry,” appears in the journal Neuropsychopharmacology ReportsAdditional information is available from the NORML Fact Sheet, ‘Relationship Between Marijuana and Opioids.’

Fewer Youth Say Cannabis Is “Easy” To Access Post-Canada Legalization

A popular talking point among cannabis opponents leading up to cannabis policy reform, including medical cannabis policy reform, is that reform will ‘increase youth access to cannabis.’ It is a talking point that opponents seem to always hurl into the public sphere when policy reform is being considered by lawmakers or voters.

What cannabis opponents fail to recognize is that regulating cannabis involves checking government-issued identification to ensure that the person is permitted to acquire cannabis. A regulated industry also involves compliance checks and audits, all of which make it much harder for youth to access cannabis. None of that is true of the unregulated market.

According to a recent survey conducted in Canada, where cannabis was legalized for adult use in 2018, fewer young people are reporting that it is “easy” to access cannabis. Below is more information about it via a news release from NORML:

Waterloo, Canada: The percentage of young people who say that it is “easy” for them to acquire cannabis has decreased significantly since Canada legalized the adult-use marijuana market, according to data published in the journal Archives of Public Health.

Canadian researchers assessed young people’s perceptions surrounding the availability of cannabis products. They determined that the percentage of underage youth reporting that cannabis was easy to access decreased by 27 percent from 2018 – the year Canada legalized cannabis markets nationwide – to 2020. Self-reported marijuana consumption by young people also decreased during this period.

The study’s authors concluded: “While there has been a growing number of studies focused on examining changes in cannabis use among Canadian youth since the onset of the Cannabis Act, and more recently since the onset of the COVID-19 pandemic, there appears to be a paucity of research dedicated to examining changes in youth perceptions of cannabis availability over the same period of time. In response, this study provides unique and novel evidence of how youth perceptions of cannabis access have changed since the onset of the Cannabis Act. … Our data suggest that in our large samples of youth, perceptions of cannabis access as being easy has declined in prevalence since legalization and through the early and ongoing pandemic response period.”

Data from the United States has similarly failed to identify any significant uptick in youth marijuana use following the adoption of state-level legalization. According to a May 2023 report from the US Centers for Disease Control and Prevention, the percentage of high schoolers who ever tried marijuana fell 30 percent between 2011 and 2021 – during which time nearly half of all US states legalized cannabis. The percentage of students who self-identified as current marijuana consumers decreased by a similar percentage during the same period.

Full text of the study, “Youth perceptions of difficulty accessing cannabis following cannabis legalization and during the early and ongoing stages of the COVID-19 pandemic: Repeat cross-sectional and longitudinal data from the COMPASS study,” appears in Archives of Public HealthAdditional information on cannabis use trends among young people is available from the NORML Fact Sheet, ‘Marijuana Regulation and Teen Use Rates.’

THC Associated With Cognitive Improvements In Patients With Advanced Cancer

Patients who are battling cancer experience any number of negative symptoms, including symptoms related to cognitive impairment. Cognitive impairment can come in many forms, including but not limited to impaired memory, reduced concentration, slower information processing, and/or reduced executive function.

Various treatments exist for cognitive impairment including pharmaceutical drugs. Cognitive remediation is another option, in which the patient learns compensatory strategies and methods to supplement their cognitive functioning.

Medical cannabis is used by many cancer patients, including varieties of medical cannabis that are high in THC. According to a recent study, oral THC dosing is associated with cognitive improvements among cancer patients. Below is more information about it via a news release from NORML:

Hjørring, Denmark: Cancer patients who take daily doses of oral THC (dronabinol) exhibit improved cognitive performance and they experience reductions in pain and depression, according to clinical data published in the journal Palliative Medicine Reports.

Danish researchers assessed the use of prescription dronabinol in six patients with advanced cancer. Subjects consumed oral THC daily for two weeks.

Investigators reported, “[T]reating palliative cancer patients with dronabinol for 14 days … seems to improve cognition in different domains, including in speed of mental processing, nonverbal and in-the-moment reasoning, as well as short-term memory and working memory.”

The study’s findings are consistent with those of others reporting cannabis-associated cognitive improvements in patients with cancerbipolar disordersHIV, and chronic pain.

Researchers also reported that THC dosing was associated with reductions in patients’ pain, depression, and fatigue. Some patients also reduced their use of other prescription medications during treatment – a finding that is consistent with numerous other studies.

The study’s authors concluded: “[I]n this group of patients, the short-term use of dronabinol did not impair cognition. Rather, the treatment was associated with improved cognition, especially in the processing and reasoning domains. The study also found relief of pain, fatigue, and depressive symptoms, which may have had an indirect beneficial effect on cognitive functions. … The study results suggest dronabinol may have a beneficial effect on different parameters for patients with advanced cancer receiving palliative care.”

Dronabinol (aka Marinol) is a Schedule III prescription drug in the United States.

Full text of the study, “Impact of low dose dronabinol therapy on cognitive function in cancer patients receiving palliative care: A care-series intervention study,” appears in Palliative Medicine Reports.

Cannabis Associated With Attention-Deficit/Hyperactivity Disorder Improvements

One of the most common neurodevelopmental disorders that people are diagnosed with around the world is attention-deficit/hyperactivity disorder (ADHD). The symptoms of the condition can look different from patient to patient, and diagnosis typically occurs early in life.

According to the results of a prior study, “the prevalence of persistent adult ADHD was 2.58% and that of symptomatic adult ADHD was 6.76%, translating to 139.84 million and 366.33 million affected adults in 2020 globally.”

A team of investigators associated with various academic institutions in the United Kingdom recently explored how the use of medical cannabis interacts with ADHD. They specifically looked at cannabis use’s potential impact on the quality of life among ADHD patients. Below is more information about it via a news release from NORML:

London, United Kingdom: Patients with attention-deficit/hyperactivity disorder (ADHD) exhibit sustained improvements in their symptoms following the use of cannabis products, according to data published in the journal Neuropsychopharmacology Reports.

British investigators assessed the safety and efficacy of plant-derived cannabis products (either oils, flower, or a combination of both) in a cohort of 68 patients enrolled in the UK Medical Cannabis Registry. Participants possessed a doctor’s authorization to access cannabis products. (Since 2018, specialists have been permitted to prescribe cannabis-based medicinal products to patients unresponsive to conventional medications.) Authors assessed the efficacy of cannabis at one, three, six, and twelve months.

Researchers reported improvements in patients’ anxiety, sleep quality, and overall health-related quality of life following cannabis treatment. Over one-third of patients ceased taking at least one ADHD prescription drug medication over the course of the study.

The study’s authors concluded: “This case series is the first of its kind in assessing the clinical outcome of patients from the UKMCR with a primary diagnosis of ADHD prescribed CBMPs [cannabis-based medicinal products] for up to 12 months. This study reports that treatment with CBMPs was associated with improvements in general HRQoL [health-related quality of life] after 1, 3, and 6, months, in addition to anxiety and sleep quality after 1, 3, 6, and 12 months. These results suggest that CBMPs may play a role in alleviating symptoms and co-morbid anxiety and sleep disruption associated with ADHD.”

Prior studies assessing the use of cannabis products in patients enrolled in the UK registry have reported them to be effective for those suffering from chronic painpost-traumatic stressdepressiongeneralized anxietymigraineinflammatory bowel disease, and other afflictions.

Full text of the study, “An analysis of clinical outcomes of medicinal cannabis therapy for attention-deficit/hyperactivity disorder,” appears in Neuropsychopharmacology Reports. 

Most Surveyed Swiss Psychiatrists Favor Regulating Cannabis

According to a team of researchers associated with the University of Bern in Switzerland, medical cannabis is “a growing issue” in psychiatry, with more patients asking about it now that cannabis policies are being modernized in Switzerland and beyond.

The researchers note that Switzerland amended its laws in 2021 to permit adult-use cannabis commerce pilot programs to be conducted at the municipal level and that there is a rising need to examine attitudes towards cannabis, including within the mental health professional community. The researchers surveyed psychiatrists in Switzerland in a recent study.

“From December 2021 to February 2022, we conducted an online survey of psychiatrists in Switzerland. The survey comprised questions on attitudes towards regulative models for CNMU and towards prescribing CMU for mental disorders.” the researchers stated about their survey methodology.

“We contacted 2010 psychiatrists in Switzerland. A total of 274 (14%) participated in the survey.” the researchers also stated.

“Sixty-four percent agreed to a regulated legalization of CNMU, and 89% would welcome pilot trials in Switzerland assessing models for regulating CNMU with those from a French-speaking region being more skeptical.” the researchers stated about their findings.

Forty-nine percent of psychiatrists agree that CMU might have a therapeutic effect in mental disorders, but 50% agree that there is not enough scientific evidence yet. Participants working in an inpatient setting or in a French-speaking region as well as those with a longer duration of practice were more skeptical on CMU for mental health.” the researchers also stated about their study’s findings.

“Most surveyed Swiss psychiatrists favor the regulation of CNMU and the conduct of pilot trials. Despite little evidence and potential negative consequences, many participating Swiss psychiatrists agreed that cannabis could be efficacious in the treatment of some mental disorders advocating for more research in this topic.” the researchers concluded.